The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Sandoz
Honoraria - Amgen; Ipsen; Lilly; Merck Serono; Novartis; Roche; SERVIER
Consulting or Advisory Role - Amgen; Bayer; Ipsen; Lilly; Merck Serono; Novartis; Roche; Sanofi; SERVIER; Sirtex Medical
Research Funding - Merck Serono; Pfizer; Roche
Travel, Accommodations, Expenses - Merck Serono; MSD; Roche
 
Employment - Roche/Genentech
Stock and Other Ownership Interests - Roche
 
Employment - Genentech/Roche; Genentech/Roche; Genentech/Roche; Medivation
IMbrave150: A randomized phase III study of 1L atezolizumab plus bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma.
 
Richard S. Finn
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; Genentech/Roche; Lilly; Merck; Novartis; Pfizer
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
 
Michel Ducreux
No Relationships to Disclose
 
Shukui Qin
No Relationships to Disclose
 
Peter R. Galle
Honoraria - AstraZeneca; Bayer; Blueprint Medicines; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; Sirtex Medical
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Lilly
Speakers' Bureau - Bayer; Sirtex Medical
Research Funding - Bayer
Travel, Accommodations, Expenses - Bayer
 
Andrew X. Zhu
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Lilly; Merck; Novartis; Sanofi
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst)
 
Masafumi Ikeda
Honoraria - Abbott Japan; Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Chugai Pharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; Dainippon Sumitomo Pharma; Eisai; Lilly Japan; Nobelpharma; Novartis; Otsuka; Taiho Pharmaceutical; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - Bayer Yakuhin; Bristol-Myers Squibb Japan; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; MSD; NanoCarrier; Novartis; Shire; Teijin Pharma
Research Funding - ASLAN Pharmaceuticals; AstraZeneca; Baxalta/Shire; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Eisai; Kowa; Kyowa Hakko Kirin; Lilly Japan; Merck Serono; NanoCarrier; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Takara Bio; Yakult Pharmaceutical; Zeria Pharmaceutical
 
Tae-You Kim
No Relationships to Disclose
 
Derek-Zhen Xu
Employment - Roche
 
Wendy Verret
No Relationships to Disclose
 
Juan Liu
No Relationships to Disclose
 
William Grossman
No Relationships to Disclose
 
Ann-Lii Cheng
Consulting or Advisory Role - Bayer Schering Pharma; Bristol-Myers Squibb; Eisai; Merck Serono; Novartis; Ono Pharmaceutical; ONXEO
Speakers' Bureau - Novartis
Research Funding - Sanofi